Erika J Schneble

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

EA Mittendorf, Guy T. Clifton, Jarrod P. Holmes et al. · Annals of Oncology · 2014 · 240 citations · Full text

Vaccination, Vaccinology, Oncology +11

Deficits in acetylcholine homeostasis, receptors and behaviors in choline transporter heterozygous mice

Mihaela H. Bazalakova, James R. Wright, Erika J Schneble et al. · Genes Brain & Behavior · 2006 · 48 citations

Sensitive Choline Transporter, Neurotransmitter, Neurotransmission +17

A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2

Julia M. Greene, Erika J Schneble, Doreen O. Jackson et al. · Cancer Immunology Immunotherapy · 2016 · 30 citations · Full text

Tumor Immunology, Cancer Immunosurveillance, Melanoma +8

Analysis of Clinical and Pathologic Factors of Pure, Flat Epithelial Atypia on Core Needle Biopsy to Aid in the Decision of Excision or Observation

John Berry, Alfred F. Trappey, Timothy J. Vreeland et al. · Journal of Cancer · 2015 · 24 citations · Full text

Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.

Erika J Schneble, Sonia A. Perez, James L. Murray et al. · Journal of Clinical Oncology · 2014 · 15 citations

Gp2+gm-csf Vaccine, Breast Oncology, Immunology +23